Asian longhorned tick threatens U.S. livestock and health
See the interactive map from the USDA here
The tick poses a risk to people, pets, and livestock. It's especially harmful to livestock and has been known to break out into an infestation on one animal, leading to great stress and reducing growth and production. A severe infestation on one animal can even cause the animal to die from blood loss. Yikes!
Aside from its infestation capabilities, the tick also carries disease. Livestock, in particular, is at risk of catching bovine theileriosis from a longhorned tick. Bovine theileriosis is a blood-borne parasite that, when left untreated, can cause an animal to die.
Outside of the US, the tick has been linked to carrying human diseases such as Japanese Spotted Fever. However, the longhorned ticks found in the US have not been found to transmit human pathogens such as Lyme disease. That's good news for now! It's been found in a lab that this tick species could become a carrier for Rocky Mountain Spotted Fever
This species of tick is unique in that the females can reproduce without a male. This is why they are efficient at spreading once introduced into a new geographic region. The tick was first identified in the US in 2017 and has since spread to 21 eastern states.
The species was first found in Missouri in 2021. It's been identified in both the St. Louis and Kansas City metro areas, and traces of the tick have been found in Greene County. A live specimen, however, hasn't been confirmed yet in Springfield. The tick has also been identified in Benton, Washington, Boone, Searcy, and Independence counties in Northern Arkansas.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
3 hours ago
- Time Business News
Next-Gen Bioremediation Technologies Revolutionize Environmental Cleanup
Bioremediation is the process of using living organisms, such as germs, fungi, or plants, to make the environment clean and safe, to break or neutralize pollutants from soil, water and air. The bioremediation market is increasing due to increasing environmental concerns, strict government rules on pollution control, increasing industrial waste and demand for environmentally friendly and cost -effective cleaning methods. Increased awareness about progress and sustainable practices in biotechnology is moving forward in areas such as oil and gas, agriculture and waste water treatment. Key Growth Drivers and Opportunities Increasing Environmental Concerns: Increasing environmental concerns are driving the growth of the bioremediation market as governments, industries, and communities seek sustainable and eco-friendly solutions to combat pollution. With increasing awareness about industrial waste, oil spread, and contaminated soil and harmful effects of water, the demand for natural and less aggressive cleaning methods is increasing. Bioremediation provides an effective, cost-efficient and environmentally safe option for traditional therapeutic techniques, causing widespread adoption and market expansion in areas. Challenges The bioremediation market faces limitations such as microbial or slow speed of plant-based cleanup processes, which may not be suitable for emergency or large-scale contamination. Effectiveness may be unexpectedly due to the presence of toxins that disrupt microbial activity such as temperature, pH, and toxins. Additionally, bioremediation is often limited to specific types of pollutants and may require a wider site monitoring. Using genetically modified organisms (GMOs) can cause regulatory approval and widely adopting public skepticism. Innovation and Expansion The New Glyphosate Bioremediation Solution Revealed by Ancient Organics In May 2023, PaleoPower will go on sale, according to Ancient Organics Bioscience, Inc., an agricultural technology firm that creates its own line of plant and soil probiotics. The only substance that is known to decompose glyphosate contamination in soil naturally is PaleoPower. A group of helpful microbes called PaleoPower breaks down glyphosate. The active component of Roundup and other popular glyphosate-based herbicides is glyphosate. PaleoPower decreased soil glyphosate levels by more than 80% during 90 days of treatment and by more than 90% within 180 days of application in controlled tests. An Innovative Approach to Address Acid Mine Drainage in Northeast Coal Mines IIT Guwahati Develops In June 2022, The Indian Institute of Technology Guwahati A study on the 'bioremediation' of Acid Mine Drainage (AMD) in Constructed Wetlands has been conducted by researchers using coal mines. This is the first research to show how constructed wetlands may be used to bioremediate AMD from the Northeastern Coalfields (NEC). The term 'acid mine drainage' describes the acidic wastewater produced by coal mines (or any polymetallic mine) that contains significant levels of iron, sulfate, and other hazardous heavy metals. This study addresses the long-term operational sustainability concerns that arise in constructed wetlands that receive AMD while offering an effective sustainable treatment method to reduce AMD contamination. To further comprehend the operation of several basic processes that co-occur in constructed wetlands, a biochemical mechanism has been established. Inventive Sparks, Expanding Markets Major development strategies for bioremediation companies include investing in advanced microbial and genetic technologies, expanding applications in industries such as agriculture, oil and gas and waste water, forming partnership with environmental agencies and focusing on permanent, low -cost solutions. Companies aim to increase operations through government cooperations and regulatory approval by increasing R&D for targeted and rapid therapeutic methods. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Gizmodo
8 hours ago
- Gizmodo
Notorious Boar's Head Plant to Reopen a Year After Listeria Outbreak That Killed 10
Boar's Head plans to reopen a meat packaging plant in Jarratt, Virginia, that was the source of a listeria outbreak in 2024 that sickened dozens of people and killed 10. The company had closed the plant indefinitely after liverwurst packaged there had been linked to the deaths. A shocking report from the New York Times shortly after the Boar's Head recall explained that the plant had evidence of meat that was exposed to wet ceilings, extensive rust, and the presence of green mold. But last month, the USDA lifted a suspension on the Virginia plant's ability to operate after the Food Safety and Inspection Service was provided evidence it could operate safely, according to the Post. The Associated Press published a new article last week that Boar's Head plants in other states had experienced sanitation problems similar to the ones found at the Jarratt plant in 2024 before the listeria outbreak. The AP obtained information through freedom of information requests about Boar's Head plants in three states, which found evidence of 'meat and fat residue left on equipment and walls, drains blocked with meat products, beaded condensation on ceilings and floors, overflowing trash cans, and staff who didn't wear protective hairnets and plastic aprons.' The USDA noncompliance reports obtained by the AP come from Jan. 1 to July 23 of this year, and also note that staff sometimes didn't wash their hands. The Boar's Head plants are located in Forrest City, Arkansas; New Castle, Indiana; and Petersburg, Virginia. And the AP spoke with food safety experts who said they were 'surprised' that Boar's Head seemingly hadn't fixed its sanitation problems after such a deadly outbreak. After the listeria outbreak in 2024, Boar's Head said it would create a 'Boar's Head Food Safety Council' comprised of 'independent industry-leading food safety experts,' according to a press release from last year. But the company has seemed to be less than willing to talk about problems at its facilities, even cancelling an interview with the AP, according to the news service. The AP was supposed to talk with Natalie Dyenson, Boar's Head's new food safety officer, but that didn't happen. The New York Times has characterized Boar's Head as 'secretive,' given the fact that the company's own chief financial officer couldn't name the CEO during a deposition in 2022. The privately held company does billions of dollars in annual revenue, but the two families that run it, the Brunckhorsts and the Bischoffs, are 'intensely guarded,' as the Times put it. It's not clear when the Jarratt plant may reopen. But a spokesperson for Boar's Head told Gizmodo in an emailed statement that the company had recently made 'enhancements.' 'Boar's Head has an unwavering commitment to food safety and quality. That commitment is reflected in recent enhancements to our practices and protocols, which you can read about at the statement reads. 'We have also been working with the USDA in developing a plan to re-open our Jarratt facility in a measured, deliberate way in the coming months.' The USDA didn't immediately respond to questions about the reopening of the plant on Friday afternoon. Gizmodo will update this article if we hear back.
Business Upturn
14 hours ago
- Business Upturn
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company's innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth. Regen sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market projected to be valued at well in excess of $1 billion annually. HemaXellerate is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation. Advertisement HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells. 'Aplastic anemia patients without access to bone marrow transplantation face limited options,' said Dr. David Koos, Chairman and CEO of Regen BioPharma. 'With FDA clearance to begin clinical trials, HemaXellerate has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.' To ensure the trial's success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months. Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity. Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market. Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence. About Regen BioPharma, Inc. Regen BioPharma, Inc. is a publicly traded biotechnology company (OTC ID: RGBP) and (OTC ID: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effect of government regulation, competition and other material risks. CONTACT INFORMATION: Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-722-5505 Phone Email: [email protected] or [email protected] X (formerly twitter): Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
